TNKase (Tenecteplase) DESCRIPTION - Genentech
infusion of Activase® (Alteplase).1 Eligibility criteria included onset of chest pain within 6 hours of randomization and ST-segment elevation or left bundle branch block on electrocardiogram (ECG). Patients were to be excluded from the trial if they received GP IIb/IIIa inhibitors within the previous 12 …
Tags:
Chest, Pain, Chest pain, Genentech
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.gene.com1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TAMIFLU safely and effectively. See full prescribing information for
Initial dose of 4 mg/kg over 90 minute IV infusion, …
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information …
HIGHLIGHTS OF PRESCRIBING INFORMATION The …
www.gene.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RITUXAN safely and effectively. See full prescribing information for
Reference ID: 4212951 - Genentech
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information …
Valcyte Master USPI - Genentech
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VALCYTE ® safely and effectively. See full prescribing information …
Information, Prescribing, Prescribing information, Genentech, Valcyte
HIGHLIGHTS OF PRESCRIBING INFORMATION - Genentech
www.gene.com2 FULL PRESCRIBING INFORMATION WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY Cardiomyopathy Herceptin administration can …
Information, Prescribing, Prescribing information, Infusion, Genentech
HIGHLIGHTS OF PRESCRIBING INFORMATION The dose for …
www.gene.comfull prescribing information warning: fatal infusion reactions, severe mucocutaneous reactions, hepatitis b virus reactivation and progressive
OCREVUS Prescribing Information - Genentech
www.gene.comHepatitis B Virus Screening Prior to initiating OCREVUS, perform Hepatitis B virus (HBV) screening. OCREVUS is contraindicated in patients with active HBV confirmed by positive results for HBsAg and anti-HBVtests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV
Information, Patients, Virus, Prescribing, Prescribing information, Hepatitis, Genentech, Hepatitis b virus
HIGHLIGHTS OF PRESCRIBING INFORMATION ACTEMRA …
www.gene.com162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response Patients at or above 100 kg weight 162 mg administered subcutaneously every week Giant Cell Arteritis (2.2) Recommended Adult Subcutaneous Dosage: The recommended dose of ACTEMRA for adult patients with GCA is 162 mg
XOLAIR Prescribing Information - Genentech
www.gene.comCorticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of XOLAIR therapy. (5.4) Eosinophilic Conditions: Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or Fever, Arthralgia, and Rash: Stop XOLAIR if patients develop signs and sickness. (5.6)
Information, Prescribing, Prescribing information, Corticosteroid, Genentech
Related documents
TENNESSEE EMERGENCY MEDICAL SERVICES PROTOCOL …
www.tn.govNov 07, 2017 · Acute Coronary Syndrome/STEMI . 105 . Chest Pain / NON Cardiac . 106 . Pulseless Electrical Activity (PEA) 107 . Premature Ventricular Contractions (PVC) 108 . Supraventricular Tachycardia (SVT) 109. Torsades de Pointes . 110 . Ventricular Asyst ole . 111 . Ventricular Fibrillation / Pulseless Vent Tachy cardia . 112 . Persistent Ventricular ...
Services, Medical, Chest, Tennessee, Protocol, Syndrome, Emergency, Pain, Acute, Coronary, Chest pain, Acute coronary syndromes, Tennessee emergency medical services protocol
Common Terminology Criteria for Adverse Events (CTCAE)
evs.nci.nih.govJun 14, 2010 · and/or acute myocardial infarction, cardiac enzymes abnormal, hemodynamically stable Symptomatic, unstable angina and/or acute myocardial infarction, cardiac enzymes abnormal, hemodynamically unstable Death Definition: A disorder characterized by signs and symptoms related to acute ischemia of the myocardium secondary to coronary artery disease.
Events, Criteria, Terminology, Common, Acute, Coronary, Adverse, Common terminology criteria for adverse events
THE B.U.R.P.S LIST - Johns Hopkins School of Nursing
nursing.jhu.eduThorac(o) Chest Thoracotomy, thoracic Thromb(o) Clot Thrombosis, thrombolytic . Other Roots. Root Meaning Example(s) Gluc(o) Sweet, sugar Glucose, glucometer Hydr(o) Water Hydrocephalus, hydrophobia Lact(o) Milk Lactosuria, lactating Lip(o), adip(o) Fat Lipoma, adipose Therm Heat Hyperthermia . II. Prefixes R/T Colors